“Golden Standard” To Become Less Expensive
International biotechnology company BIOCAD in fact, not in word, responded to the request of the Russian Government to reduce prices for drugs. It applied for marketing authorization renewal with reduced prices for drugs in the group of hi-tech biosimilars for treatment of cancer, based on monoclonal antibodies. The issue concerns the golden standard of treatment of serious neoplastic disorders – rituximab, bevacizumab and trastuzumab. It is suggested that the cost of bevacizumab used for treatment of intestinal, lung, ovarian, renal cancer will be 20% less expensive versus the earlier authorized price. Cost reduction by 15% for trastuzumab, a drug for treatment of breast cancer, will provide a 30% difference versus the original drug.
Thanks to that initiative and the fact, that Russian drugs for treatment of cancer will be almost twice as less expensive versus original drugs, more patients will get access to the drugs.